Précédent|Prochain

AKR1C3 comme cible thérapeutique pour surmonter la résistance à l'érlotinib dans l’adénocarcinome pulmonaire

  • role： Corresponding author, First author通信作者, 第一作者
  • Affiliation：

    Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong SAR, China

  • Email：chocs@ha.org.hk
  • Introduction：* William C. Cho chocs@ha.org.hk; williamcscho@gmail.com
William C. Cho1*,  
  • Affiliation：

    Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong SAR, China

Kwan P. Li1,  
  • Affiliation：

    Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong SAR, China

Chi F. Wong1,  
  • Affiliation：

    Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong SAR, China

King Y. Fung1,  
  • Affiliation：

    Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong SAR, China

James C. H. Chow1,  
  • Affiliation：

    Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong SAR, China

Ka M. Cheung1,  
  • Affiliation：

    Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong SAR, China

Jeffrey C. H. Chan1,  
  • Affiliation：

    Department of Obstetrics and Gynaecology, Tsan Yuk Hospital, Hong Kong SAR, China

Eunice Y. T. Lau2

résumé

mots-clés

AKR1C3; résistance à l'érlotinib; mutation du récepteur du facteur de croissance épidermique (EGFR); adénocarcinome pulmonaire (LUAD); cible thérapeutique

References

  1. 1..
    Laface C,Maselli FM,Santoro AN,Iaia ML,Ambrogio F,Laterza M, et al. The resistance to EGFR-TKIs in non-small cell lung cancer: from molecular mechanisms to clinical application of new therapeutic strategies. Pharmaceutics. 2023;15(6):1604.
  2. 2..
    Li M,Zhang L,Yu J,Wang X,Cheng L,Ma Z, et al. AKR1C3 in carcinomas:from multifaceted roles to therapeutic strategies. Front Pharmacol.2024;15:1378292.
  3. 3..
    Rowland KJ,Diaz-Miron J,Guo J,Erwin CR,Mei J,Worthen GS, et al. CXCL5 is required for angiogenesis, but not structural adaptation after small bowel resection. J Pediatr Surg. 2014;49(6):976-80.
  4. 4..
    Zhang Y,Tang L. Inhibition of breast cancer cell proliferation and tumorigenesis by long non-coding RNA RPPH1 down-regulation of miR-122 expression. Cancer Cell Int. 2017;17:109.
  5. 5..
    Cox DG,Pontes C,Guino E,Navarro M,Osorio A,Canzian F, et al. Polymor-phisms in prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) and risk of colorectal cancer. Br J Cancer. 2004;91(2):339-43.

Lire l'article complet

The above content is generated by Large Model Translation. The translated content is for reference only. We do not assume any commercial or legal responsibilty for any consequences arising from the use of our website